Theravance Biopharma, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Theravance Biopharma, Inc. (TBPH) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $8.89 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-23
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8.89M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13.07M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $10.09M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21.53M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $8.89M 10-K · filed 2026-03-23 |
| 2024-12-31 | $13.07M 10-K · filed 2025-03-07 |
| 2023-12-31 | $10.09M 10-K · filed 2024-03-01 |
| 2022-12-31 | $21.53M 10-K · filed 2023-03-01 |
| 2021-12-31 | $22.62M 10-K · filed 2022-02-28 |
| 2020-12-31 | $31.98M 10-K · filed 2021-02-26 |
| 2019-12-31 | $36.31M 10-K · filed 2020-02-27 |
| 2019-09-30 | $37.69M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $38.93M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $40.13M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |